BioWorld

May 10, 2006

Merck Buying GlycoFi For $400M, Abmaxis For $80M

Merck & Co. Inc. set in motion two definitive agreements to acquire privately held biotechnology companies GlycoFi Inc. and Abmaxis Inc., and $400 million for $80 million, respectively, and would pay cash for both. (BioWorld Today) Read More

Avidia's Third Round: $44M For Avimer-Based Pipeline

Avicena Drug Misses Endpoint But Shows Improved Mortality

Pharmasset Files For $75M IPO; Caprion Bids To Go Public, Too

Clinic Roundup

Other News To Note

Appointments And Advancements

Today's news in brief

BioWorld

IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa

BioWorld Science

Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...

Illustration of head with maze that is missing parts

Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke

BioWorld Science

Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...

VST Bio’s VB-001 is neuroprotector after stroke

BioWorld Science

At the recent International Stroke Conference, researchers from VST Bio Corp. and Yale University presented preclinical data regarding VB-001, a monoclonal...

New mechanism of action identified for QC-6352

BioWorld Science

QC-6352 is a small molecule developed to inhibit the histone demethylase 4 (KDM4) that has shown potent antitumoral activity and which has a derivative named...